^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Promacta (eltrombopag)

    i
    Other names: SB-497115, SB-497115-GR, 497115, ETB-115, SB497115, SB 497115, SB497115GR, SB 497115 GR, ETB115, ETB 115
    Company:
    GSK, Novartis, Royalty
    Drug class:
    Thrombopoietin receptor agonist
    Related drugs:
    25d
    20-H-0033: Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA) (clinicaltrials.gov)
    P2, N=39, Active, not recruiting, National Heart, Lung, and Blood Institute (NHLBI) | Recruiting --> Active, not recruiting | N=80 --> 39
    Enrollment closed • Enrollment change
    |
    Promacta (eltrombopag) • cyclosporine
    1m
    20-H-0033: Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA) (clinicaltrials.gov)
    P2, N=80, Recruiting, National Heart, Lung, and Blood Institute (NHLBI) | Trial completion date: May 2028 --> Dec 2033
    Trial completion date
    |
    Promacta (eltrombopag) • cyclosporine
    2ms
    TQZ3469-BE-01: Bioequivalence Study of Eltrombopag Olamine Tablets in Healthy Subjects in the Fed State (clinicaltrials.gov)
    P=N/A, N=36, Completed, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Initiation date: Mar 2020 --> Mar 2023
    Trial initiation date
    |
    Promacta (eltrombopag)
    2ms
    The Use of Eltrombopag Post HSCT in BMFD (clinicaltrials.gov)
    P2/3, N=118, Completed, The First Affiliated Hospital of Soochow University | Recruiting --> Completed | Trial completion date: Jul 2027 --> Oct 2025
    Trial completion • Trial completion date
    |
    Promacta (eltrombopag)
    2ms
    Eltrombopag olamine induces apoptosis in human breast adenocarcinoma and hepatocellular carcinoma cells through modulation of multiple apoptotic pathways. (PubMed, Sci Rep)
    Interactions of Eltrombopag with EGFR, FAS, p53, and TNFα proteins were detected through molecular docking simulations. These findings highlight the potential of Eltrombopag olamine as a repurposed, multi-targeted therapeutic candidate for the treatment of breast and liver cancer.
    Journal • PARP Biomarker
    |
    EGFR (Epidermal growth factor receptor) • TNFA (Tumor Necrosis Factor-Alpha) • STAT3 (Signal Transducer And Activator Of Transcription 3) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • MAPK1 (Mitogen-activated protein kinase 1) • CASP3 (Caspase 3) • CASP7 (Caspase 7) • ANXA5 (Annexin A5)
    |
    EGFR expression
    |
    Promacta (eltrombopag)
    3ms
    Consensus Virtual Screening and Ex Vivo Evaluation of Novel JAK2/STAT1,3 Inhibitors. (PubMed, ACS Omega)
    In the ex vivo evaluations, pitavastatin (0.5004 μM), eltrombopag (0.2548 μM), flavoxate (0.1536 μM), and empagliflozin (0.2548 μM) affected the phosphorylation of downstream STAT1 and STAT3 signaling molecules, similarly to tofacitinib citrate (TOF) (1.2 nM ). These results encourage further in-depth preclinical experiments aimed at exploring the additional effects of the JAK2-STAT1/3 signaling pathway.
    Preclinical • Journal
    |
    JAK2 (Janus kinase 2) • IL6 (Interleukin 6) • STAT1 (Signal Transducer And Activator Of Transcription 1)
    |
    Promacta (eltrombopag) • tofacitinib • pitavastatin
    3ms
    Coexistence of Immune Thrombocytopenic Purpura and Bernard-Soulier Syndrome: A Rare Pediatric Case Report. (PubMed, Int Med Case Rep J)
    She was managed with intravenous immunoglobulin (IVIG) and corticosteroids; Eltrombopag was discontinued due of leukemic risk...The purpose of this case report is to illustrate the diagnostic challenges and therapeutic considerations in children with coexisting acquired (ITP) and inherited (BSS) thrombocytopenias, particularly in the presence of a leukemogenic predisposition gene (ETV6). This case underscores the importance of comprehensive genetic evaluation in guiding individualized therapy and long-term surveillance.
    Journal
    |
    ETV6 (ETS Variant Transcription Factor 6)
    |
    Promacta (eltrombopag)
    3ms
    TRIM28 drives immune evasion via PARP1 SUMOylation and NAD+ depletion in clear cell renal cell carcinoma. (PubMed, J Immunother Cancer)
    This study reveals that TRIM28 is a key regulator of PD-L1 expression and T cell dysfunction in ccRCC through PARP1 stabilization and NAD+ metabolic reprogramming. Targeting TRIM28/PARP1/PDL1 with Eltrombopag reshapes the immunosuppressive TME and enhances checkpoint blockade efficacy, providing a novel combinatorial strategy for ccRCC immunotherapy.
    Journal • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • TRIM28 (Tripartite Motif Containing 28)
    |
    PD-L1 expression
    |
    Promacta (eltrombopag)
    4ms
    REGALIA: RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation (clinicaltrials.gov)
    P2, N=9, Terminated, University Hospital, Lille | N=25 --> 9 | Recruiting --> Terminated; inclusions difficulties.
    Enrollment change • Trial termination
    |
    Promacta (eltrombopag)
    4ms
    Sequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP (clinicaltrials.gov)
    P4, N=150, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    New P4 trial
    |
    Promacta (eltrombopag)
    5ms
    The Combination of ATRA and Eltrombopag as the Treatment of Steroid-resistant/Relapse ITP Based on MSC-C5b-9 (clinicaltrials.gov)
    P3, N=96, Completed, Peking University People's Hospital | Recruiting --> Completed | Trial completion date: Mar 2025 --> Nov 2024
    Trial completion • Trial completion date
    |
    Promacta (eltrombopag)
    5ms
    Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease (clinicaltrials.gov)
    P1/2, N=10, Enrolling by invitation, National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Sep 2028 --> Sep 2029
    Trial completion date
    |
    sirolimus • Actemra IV (tocilizumab) • Promacta (eltrombopag) • busulfan